On June 24, 2026, Assort Health, the most widely used AI agents platform for the patient journey, announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion. Assort has now raised more than $222 million to become the standard for healthcare organizations wanting to transform the patient journey with AI. Wilson Sonsini Goodrich & Rosati advised Assort on the transaction.

In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.  

What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare. 

The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.

For more information, please see Assort’s blog post.